pyrrolidonecarboxylic acid has been researched along with HbS Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abas, AB; De Franceschi, L; Palaniappan, SK; Soe, HHK; Than, NN | 1 |
| Steinberg, MH | 1 |
| Brugnara, C; Hankins, JS; Hillery, CA; Li, CS; Wang, WC; Wynn, LW | 1 |
| Alper, S; Bachir, D; Beuzard, Y; Brugnara, C; Cynober, T; De Franceschi, L; Galacteros, F; Platt, O; Tchernia, G | 1 |
| Bachir, D; Beuzard, Y; Brugnara, C; Cynober, T; De Franceschi, L; Galacteros, F; Neuberg, D; Tchernia, G | 1 |
2 review(s) available for pyrrolidonecarboxylic acid and HbS Disease
| Article | Year |
|---|---|
Magnesium for treating sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Humans; Hydroxyurea; Injections, Intravenous; Magnesium; Magnesium Sulfate; Middle Aged; Pain Measurement; Parents; Pyrrolidonecarboxylic Acid; Quality of Life; Randomized Controlled Trials as Topic | 2017 |
Pathophysiologically based drug treatment of sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Anti-Inflammatory Agents; Antisickling Agents; Azacitidine; Cell Adhesion; Drug Therapy, Combination; Endothelium, Vascular; Erythrocytes; Fetal Hemoglobin; Gene Expression Regulation; Hemoglobin, Sickle; Humans; Hydroxyurea; K Cl- Cotransporters; Pyrrolidonecarboxylic Acid; Randomized Controlled Trials as Topic; Symporters | 2006 |
2 trial(s) available for pyrrolidonecarboxylic acid and HbS Disease
| Article | Year |
|---|---|
Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.
Topics: Adolescent; Anemia, Sickle Cell; Antisickling Agents; Child; Child, Preschool; Drug Combinations; Humans; Hydroxyurea; Maximum Tolerated Dose; Pilot Projects; Pyrrolidonecarboxylic Acid | 2008 |
Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biological Transport; Dietary Supplements; Erythrocyte Deformability; Erythrocytes, Abnormal; Female; Hematologic Tests; Humans; Magnesium; Male; Potassium; Pyrrolidonecarboxylic Acid; Sodium; Sodium-Potassium-Exchanging ATPase; Water-Electrolyte Balance | 1997 |
1 other study(ies) available for pyrrolidonecarboxylic acid and HbS Disease
| Article | Year |
|---|---|
Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease.
Topics: Administration, Oral; Adult; Aged; Anemia, Sickle Cell; Erythrocytes; Humans; Middle Aged; Pain; Potassium; Pyrrolidonecarboxylic Acid; Sodium | 2000 |